Last reviewed · How we verify
Corticotropin-release hormone
Corticotropin-release hormone, marketed by Universitaire Ziekenhuizen KU Leuven, holds a niche position in the pharmaceutical market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market presence. The primary risk lies in the lack of reported revenue and key trial results, which may limit investor confidence and market expansion.
At a glance
| Generic name | Corticotropin-release hormone |
|---|---|
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Chromosome 18 Clinical Research Center
- The Effect of Sulfasalazine on CRH Levels in Pregnant Women (PHASE2)
- Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women (EARLY_PHASE1)
- Hormonal Mechanisms of Sleep Restriction - Axis Study (PHASE1)
- Reducing Pregnancy Risks: The Mastery Lifestyle Intervention (NA)
- Imaging CRF X NOP Interactions in CUD (EARLY_PHASE1)
- Cardiorespiratory Fitness Training in Patients with Incomplete Spinal Cord Injury (NA)
- Effect of CRH on Duodenal Markers and Gastric Sensorimotor Function (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corticotropin-release hormone CI brief — competitive landscape report
- Corticotropin-release hormone updates RSS · CI watch RSS
- Universitaire Ziekenhuizen KU Leuven portfolio CI